Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for Knee Ost...
23 December 2015 - 1:00AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a biomedicine firm engaged in the development of
effective stem cell therapies for degenerative diseases and
immunotherapies for cancer, today announced a scheduled
presentation to release 48-week clinical data from the Phase IIb
trial of its ReJoin® human adipose-derived mesenchymal
progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA) at
the 8th Annual BioTech Showcase investor conference to be held
in San Francisco, CA January 11-13, 2016.
Conference: 8th Annual BioTech
Showcase 2016Date: Tuesday, January 12,
2016Time: 10:00 AM
PDTTitle: Alteration of Knee Osteoarthritis,
ReJoin® Phase IIb One Year Follow Up Results
Location: Track C - Mission II, 4th Floor,
Parc 55, Union Square, 55 Cyril Magnin Street, San Francisco, CA
Presenter: Wei (William) Cao, PhD, BM, Chief
Executive Officer
Company management will attend the conference
and be available for discussions. To arrange one-to-one meetings
with management, please contact vivian.chen@grayling.com. The
presented data analysis will be available on the Company website
following the presentation.
About Cellular Biomedicine
Group
Cellular Biomedicine Group, Inc. develops
proprietary cell therapies for the treatment of certain
degenerative and cancerous diseases. Our developmental stem
cell and Immuno-Oncology projects are the result of research and
development by scientists and doctors
from China and the United States. Our flagship GMP
facility in China, consisting of six independent cell production
lines, is designed, certified and managed according to U.S.
standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts may
be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy,
including the devaluation of the RMB by China in August 2015 and
other risks detailed from time to time in CBMG’s reports filed with
the Securities and Exchange Commission, quarterly reports on form
10-Q, current reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2024 to May 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From May 2023 to May 2024